Psilocybin induces spatially constrained alterations in thalamic functional organizaton and connectivity

Psilocybin induces spatially constrained alterations in thalamic functional organizaton and connectivity

Background: Classic psychedelics, such as psilocybin and LSD, and other serotonin 2A receptor (5-HT2AR) agonists evoke acute alterations in perception and cognition. Altered thalamocortical connectivity has been hypothesized to underlie these effects, which is supported by some functional MRI (fMRI)...

Full description

Bibliographic Details
Main Authors:	Andrew Gaddis, Daniel E. Lidstone, Mary Beth Nebel, Roland R. Griffiths, Stewart H. Mostofsky, Amanda F. Mejia, Frederick S. Barrett
Format:	Article
Language:	English
Published:	Elsevier 2022-10-01
Series:	NeuroImage
Subjects:	Functional MRI Functional connectivity Independent component analysis Resting state Psilocybin Psychedelics
Online Access:	http://www.sciencedirect.com/science/article/pii/S1053811922005511

Similar Items

Corrigendum to ‘Psilocybin induces spatially constrained alterations in thalamic functional organizaton and connectivity’: Neuroimage 2022 Oct 15;260:119434
by: Andrew Gaddis, et al.
Published: (2023-07-01)

Human Cortical Serotonin 2A Receptor Occupancy by Psilocybin Measured Using [11C]MDL 100,907 Dynamic PET and a Resting-State fMRI-Based Brain Parcellation
by: Frederick S. Barrett, et al.
Published: (2022-01-01)

Psilocybin modulation of time-varying functional connectivity is associated with plasma psilocin and subjective effects
by: Anders S. Olsen, et al.
Published: (2022-12-01)

Esketamine and Psilocybin—The Comparison of Two Mind-Altering Agents in Depression Treatment: Systematic Review
by: Dominika Psiuk, et al.
Published: (2022-09-01)

Naturalistic psilocybin use is associated with persisting improvements in mental health and wellbeing: results from a prospective, longitudinal survey
by: Sandeep M. Nayak, et al.
Published: (2023-09-01)

Depression, Mindfulness, and Psilocybin: Possible Complementary Effects of Mindfulness Meditation and Psilocybin in the Treatment of Depression. A Review
by: Kristin Heuschkel, et al.
Published: (2020-03-01)

The Therapeutic Potential of Psilocybin
by: Henry Lowe, et al.
Published: (2021-05-01)

Race and ethnicity moderate the associations between lifetime psilocybin use and crime arrests
by: Grant Jones, et al.
Published: (2023-08-01)

Psilocybin and Mental Health–Don't Lose Control
by: Joseph M. Barnby, et al.
Published: (2018-07-01)

Psilocybin for Treating Psychiatric Disorders: A Psychonaut Legend or a Promising Therapeutic Perspective?
by: Maurizio Coppola, et al.
Published: (2022-02-01)

Therapeutic use of psilocybin: Practical considerations for dosing and administration
by: Caroline A. MacCallum, et al.
Published: (2022-12-01)

The effects of psilocybin and MDMA on between-network resting state functional connectivity in healthy volunteers
by: Leor eRoseman, et al.
Published: (2014-05-01)

Trajectory of Antidepressant Effects after Single- or Two-Dose Administration of Psilocybin: A Systematic Review and Multivariate Meta-Analysis
by: Chia-Ling Yu, et al.
Published: (2022-02-01)

LSD and psilocybin for chronic nociplastic pain: A narrative review of the literature supporting the use of classic psychedelic agents in chronic pain
by: J Van Der Walt, et al.
Published: (2023-11-01)

Psilocybin - new remedy for patients with psychiatric disorders? Critical analysis of the current state of knowledge
by: Karolina Wąsik, et al.
Published: (2023-12-01)

Individual Experiences in Four Cancer Patients Following Psilocybin-Assisted Psychotherapy
by: Tara C. Malone, et al.
Published: (2018-04-01)

Evidence versus expectancy: the development of psilocybin therapy
by: James J. Rucker

Psilocybin, a Naturally Occurring Indoleamine Compound, Could Be Useful to Prevent Suicidal Behaviors
by: Robertas Strumila, et al.
Published: (2021-11-01)

Subacute effects of a single dose of psilocybin on biomarkers of inflammation in healthy humans: An open-label preliminary investigation
by: Daniel Rødbro Burmester, et al.
Published: (2023-02-01)

Chronic Treatment With Psilocybin Decreases Changes in Body Weight in a Rodent Model of Obesity
by: Joyce Huang, et al.
Published: (2022-05-01)

Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression
by: Leor Roseman, et al.
Published: (2018-01-01)

Psilocybin sex-dependently reduces alcohol consumption in C57BL/6J mice
by: Kenneth Alper, et al.
Published: (2023-01-01)

Serotonergic psychedelics for depression: What do we know about neurobiological mechanisms of action?
by: Muhammad Ishrat Husain, et al.
Published: (2023-02-01)

The Effectiveness of Microdosed Psilocybin in the Treatment of Neuropsychiatric Lyme Disease: A Case Study
by: Kinderlehrer DA
Published: (2023-03-01)

Development and Evaluation of a Therapist Training Program for Psilocybin Therapy for Treatment-Resistant Depression in Clinical Research
by: Sara J. Tai, et al.
Published: (2021-02-01)

Manic episode following psilocybin use in a man with bipolar II disorder: a case report
by: Haniya J. Halim, et al.
Published: (2023-09-01)

Psilocybin acutely alters the functional connectivity of the claustrum with brain networks that support perception, memory, and attention
by: Frederick S. Barrett, et al.
Published: (2020-09-01)

Psychedelics and psychiatric disorders: A emerging role
by: C. Peixoto, et al.
Published: (2021-04-01)

Effects of psilocybin, psychedelic mushroom extract and 5-hydroxytryptophan on brain immediate early gene expression: Interaction with serotonergic receptor modulators
by: Elad Lerer, et al.
Published: (2024-04-01)

Music programming for psilocybin-assisted therapy: Guided Imagery and Music-informed perspectives
by: Catharina Messell, et al.
Published: (2022-11-01)

Development of a digital intervention for psychedelic preparation (DIPP)
by: Rosalind G. McAlpine, et al.
Published: (2024-02-01)

Palliative care patients’ attitudes and openness towards psilocybin-assisted psychotherapy for existential distress
by: Julia Ruixi Wang, et al.
Published: (2024-04-01)

Psilocybin—Mediated Attenuation of Gamma Band Auditory Steady-State Responses (ASSR) Is Driven by the Intensity of Cognitive and Emotional Domains of Psychedelic Experience
by: Vojtěch Viktorin, et al.
Published: (2022-06-01)

Single-dose psilocybin-assisted therapy in major depressive disorder: a placebo-controlled, double-blind, randomised clinical trialResearch in context
by: Robin von Rotz, et al.
Published: (2023-02-01)

Keeping the promise: a critique of the current state of microdosing research
by: Rotem Petranker, et al.
Published: (2024-02-01)

Editorial: Appropriateness and safety of using cannabinoid and psychedelic medicines as treatments for psychiatric disorders
by: Grace Blest-Hopley, et al.
Published: (2023-05-01)

Psychedelic Assisted Psychotherapy preparing your target using psychohistoriography: a Jamaican perspective
by: Winston De La Haye, et al.
Published: (2023-06-01)

The Psychedelic Integration Scales: Tools for Measuring Psychedelic Integration Behaviors and Experiences
by: Tomas Frymann, et al.
Published: (2022-05-01)

Safety, tolerability, and clinical and neural effects of single-dose psilocybin in obsessive–compulsive disorder: protocol for a randomized, double-blind, placebo-controlled, non-crossover trial
by: Terence H. W. Ching, et al.
Published: (2023-04-01)

A Single Dose of Psilocybin Increases Synaptic Density and Decreases 5-HT<sub>2A</sub> Receptor Density in the Pig Brain
by: Nakul Ravi Raval, et al.
Published: (2021-01-01)